# Solstice Health Financial Model

**January 2026**

---

## Executive Summary

| Metric | Value |
|--------|-------|
| Current ARR (Jan 2026) | $2.8M |
| Projected ARR (Sep 2027) | $58.3M |
| Total Contracted ARR | $1.5M |
| Total Booked ARR | $2.7M |
| Current Team Size | 12 |
| Planned Hires (21 months) | 43 |
| Series A Raise | $15M |
| Gross Margin Target | 70.2% |
| Net Margin Target | 15.0% |

---

## 1. Forecast Model

### Revenue Summary (Monthly)

| Period | New Business | Expansion | Total Monthly | ARR | MoM Growth |
|--------|-------------|-----------|---------------|-----|------------|
| Jan 2026 | $221,900 | $11,520 | $233,420 | $2.8M | - |
| Feb 2026 | $221,900 | $23,386 | $245,286 | $2.9M | 5.1% |
| Mar 2026 | $257,679 | $42,482 | $300,161 | $3.6M | 22.4% |
| Apr 2026 | $294,708 | $70,805 | $365,513 | $4.4M | 21.8% |
| May 2026 | $335,090 | $110,513 | $445,603 | $5.3M | 21.9% |
| Jun 2026 | $377,442 | $134,255 | $511,697 | $6.1M | 14.8% |
| Jul 2026 | $431,803 | $168,739 | $600,543 | $7.2M | 17.4% |
| Aug 2026 | $488,852 | $212,129 | $700,981 | $8.4M | 16.7% |
| Sep 2026 | $574,663 | $275,468 | $850,131 | $10.2M | 21.3% |
| Oct 2026 | $664,826 | $321,500 | $986,327 | $11.8M | 16.0% |
| Nov 2026 | $759,585 | $383,428 | $1,143,013 | $13.7M | 15.9% |
| Dec 2026 | $867,551 | $464,156 | $1,331,707 | $16.0M | 16.5% |
| Jan 2027 | $989,690 | $566,811 | $1,556,501 | $18.7M | 16.9% |
| Feb 2027 | $1,118,264 | $700,631 | $1,818,895 | $21.8M | 16.9% |
| Mar 2027 | $1,301,906 | $779,316 | $2,081,222 | $25.0M | 14.4% |
| Apr 2027 | $1,495,699 | $880,553 | $2,376,252 | $28.5M | 14.2% |
| May 2027 | $1,713,130 | $1,012,011 | $2,725,140 | $32.7M | 14.7% |
| Jun 2027 | $1,956,179 | $1,178,651 | $3,134,830 | $37.6M | 15.0% |
| Jul 2027 | $2,227,061 | $1,391,148 | $3,618,209 | $43.4M | 15.4% |
| Aug 2027 | $2,514,081 | $1,650,527 | $4,164,608 | $50.0M | 15.1% |
| Sep 2027 | $2,877,443 | $1,983,429 | $4,860,873 | $58.3M | 16.7% |

### Sales Team & Capacity

| Role | Jan 26 | Mar 26 | Jun 26 | Sep 26 | Dec 26 | Mar 27 | Jun 27 | Sep 27 |
|------|--------|--------|--------|--------|--------|--------|--------|--------|
| VP of Sales | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Account Executives | 0 | 2 | 2 | 3 | 3 | 4 | 4 | 5 |
| Commercial Engagement Lead | 2 | 4 | 4 | 5 | 6 | 7 | 7 | 7 |

### Pipeline Assumptions

| Metric | Jan 26 | Jun 26 | Dec 26 | Jun 27 | Sep 27 |
|--------|--------|--------|--------|--------|--------|
| Conversation → Pilot | 30% | 40% | 55% | 75% | 80% |
| Pilot → Closed | 70% | 76% | 82% | 88% | 91% |
| Overall Conversion | 21% | 30% | 45% | 66% | 73% |
| Sales Cycle (months) | 4.0 | 3.5 | 2.9 | 2.3 | 2.0 |
| Average ACV | $200K | $232K | $277K | $331K | $361K |

### Client Growth

| Metric | Jan 26 | Jun 26 | Dec 26 | Jun 27 | Sep 27 |
|--------|--------|--------|--------|--------|--------|
| Total Clients | 8 | 16 | 36 | 71 | 96 |
| Cumulative New Clients | 0 | 8 | 28 | 63 | 88 |
| Expansion Rate (monthly) | 3% | 2% | 1.5% | 1% | 1% |

### Costs (Monthly)

| Category | Jan 26 | Jun 26 | Dec 26 | Jun 27 | Sep 27 |
|----------|--------|--------|--------|--------|--------|
| **COGS** | | | | | |
| Commercial Engagement Lead | $29,167 | $95,833 | $112,500 | $145,833 | $145,833 |
| Medical Copywriter | $8,333 | $30,000 | $30,000 | $30,000 | $30,000 |
| AI Designer | $1,667 | $21,667 | $41,667 | $41,667 | $41,667 |
| Editorial | $0 | $21,667 | $21,667 | $21,667 | $21,667 |
| Compute Costs | $4,000 | $16,000 | $36,000 | $71,000 | $96,000 |
| **Total COGS** | $43,167 | $185,167 | $241,833 | $310,167 | $335,167 |
| **Gross Margin** | 81.5% | 63.8% | 81.8% | 90.1% | 93.1% |
| | | | | | |
| **Operating Expenses** | | | | | |
| Sales & Marketing | $10,667 | $149,336 | $252,171 | $465,816 | $638,421 |
| Product & Engineering | $65,000 | $161,447 | $264,461 | $374,403 | $449,161 |
| G&A | $105,000 | $144,412 | $275,114 | $511,535 | $744,551 |
| **Total OpEx** | $180,667 | $455,196 | $791,746 | $1,351,754 | $1,832,133 |
| | | | | | |
| **Net Operating Profit** | $9,587 | -$128,666 | $298,129 | $1,472,909 | $2,693,573 |

### Cash Position

| Metric | Jan 26 | Jun 26 | Dec 26 | Jun 27 | Sep 27 |
|--------|--------|--------|--------|--------|--------|
| Beginning Cash | $1.3M | $16.0M | $16.0M | $20.2M | $25.7M |
| Capital Raised | $0 | $0 | $0 | $0 | $0 |
| Net Operating Profit | $9.6K | -$128.7K | $298.1K | $1.5M | $2.7M |
| Ending Cash | $1.3M | $15.9M | $16.3M | $21.7M | $28.4M |
| Monthly Burn | $0 | $128.7K | $0 | $0 | $0 |

*Note: $15M raised in Feb 2026*

### Hiring Schedule

| Role | Salary | Total Hires |
|------|--------|-------------|
| **Product & Engineering** | | |
| AI & ML Operations Engineer | $200K | 6 |
| Fullstack Developer | $200K | 4 |
| VP Engineering | $250K | 1 |
| VP Product | $250K | 1 |
| Product Design | $200K | 5 |
| **Sales & Marketing** | | |
| Account Executives | $250K | 5 |
| VP Sales | $200K | 1 |
| VP Marketing | $200K | 1 |
| Business Development Reps | $150K | 2 |
| **Operations** | | |
| Commercial Engagement Lead | $200K | 7 |
| Medical Copywriter | $130K | 2 |
| Editorial | $130K | 2 |
| AI Designer | $120K | 4 |
| Talent & HR | $200K | 2 |
| Implementations Engineer | $120K | 4 |
| **TOTAL** | | **43** |

---

## 2. Historical P&L (May 2025 - Jan 2026)

### Revenue by Customer (Monthly)

| Customer | Sep 25 | Oct 25 | Nov 25 | Dec 25 | Jan 26 |
|----------|--------|--------|--------|--------|--------|
| Phathom Pharmaceuticals | $9,000 | $9,000 | $9,000 | $9,000 | $9,000 |
| Ipsen Pharmaceuticals | $0 | $15,000 | $15,000 | $15,000 | $15,000 |
| Nuvation Bio | $0 | $0 | $25,000 | $25,000 | $25,000 |
| AstraZeneca (Alexion) | $0 | $0 | $0 | $25,000 | $30,000 |
| Sanofi (Dupixent) | $0 | $0 | $0 | $0 | $17,300 |
| UCB | $0 | $0 | $0 | $0 | $24,300 |
| Incyte | $0 | $0 | $0 | $11,000 | $0 |
| Ardelyx | $0 | $0 | $0 | $0 | $33,000 |
| Pfizer (pilot) | $0 | $0 | $0 | $0 | $2,700 |
| **Total** | **$9,000** | **$24,000** | **$49,000** | **$85,000** | **$156,300** |

### P&L Summary (Monthly)

| Line Item | Sep 25 | Oct 25 | Nov 25 | Dec 25 | Jan 26 |
|-----------|--------|--------|--------|--------|--------|
| **Gross Revenue** | $9,000 | $24,000 | $49,000 | $85,000 | $156,300 |
| Total COGS | -$24,583 | -$25,583 | -$26,083 | -$26,583 | -$30,083 |
| **Gross Margin** | -173% | -7% | 47% | 69% | 81% |
| S&M Expense | -$10,667 | -$10,667 | -$10,667 | -$10,667 | -$10,667 |
| Prod/Eng Expense | -$45,000 | -$45,000 | -$65,000 | -$65,000 | -$65,000 |
| G&A Expense | -$44,667 | -$58,000 | -$80,000 | -$95,000 | -$105,000 |
| **Total OpEx** | -$100,333 | -$113,667 | -$155,667 | -$170,667 | -$180,667 |
| **Net Profit (Loss)** | **-$115,917** | **-$115,250** | **-$132,750** | **-$112,250** | **-$54,450** |

---

## 3. Sales Pipeline

### Signed Contracts

| Customer | Market Cap | Date Signed | Contract Value | Annual Revenue | Brands |
|----------|-----------|-------------|----------------|----------------|--------|
| Phathom Pharmaceuticals | $1.1B | Sep 5, 2025 | $118,000 | $118,000 | VOQUEZNA |
| Ipsen Pharmaceuticals | $11.3B | Oct 1, 2025 | $180,000 | $180,000 | ONIVYDE |
| Nuvation Bio | $2.0B | Nov 18, 2025 | $200,000 | $150,000 | IBTROZI |
| AstraZeneca (Alexion) | $293B | Dec 18, 2025 | $350,000 | $350,000 | ULTOMIRIS gMG |
| Sanofi | $113.8B | Dec 15, 2025 | $152,000 | $412,960 | DUPIXENT, TOUJEO, JEVTANA, MULTAQ |
| UCB | $50.3B | Dec 17, 2025 | $73,000 | $262,000 | BIMZELX |
| Incyte (Pilot) | $20.9B | Nov 14, 2025 | $11,000 | TBD | OPZELURA |
| Pfizer (Pilot) | $145.8B | Jan 17, 2026 | $5,400 | $32,400 | Medical Affairs |
| **Total Contracted ARR** | | | | **$1,505,360** | |

### In Contract (Awaiting Signature)

| Customer | Market Cap | Expected Sign | Contract Value | Annual Revenue | Brands |
|----------|-----------|---------------|----------------|----------------|--------|
| Ardelyx | $1.6B | Jan 31, 2026 | $395,000 | $395,000 | XPHOZAH, IBSRELA |
| Incyte Pharmaceuticals | $20.9B | Jan 31, 2026 | $300,000 | $300,000 | OPZELURA |
| AstraZeneca Oncology | $293B | Jan 31, 2026 | $300,000 | $300,000 | Camizestrant Launch |
| AstraZeneca (Alexion) | $293B | Jan 31, 2026 | $200,000 | $200,000 | ULTOMIRIS NMOSD |
| **Total Booked ARR** | | | | **$2,700,360** | |

### In Contract Discussions

| Customer | Market Cap | Expected Sign | Contract Value | Brands |
|----------|-----------|---------------|----------------|--------|
| Akebia Therapeutics | $361M | Jan 31, 2026 | $300,000 | VAFSEO |
| Takeda Oncology | $51.4B | Apr 1, 2026 | $700,000 | FRUZAQLA, ALUNBRIG, ICLUSIG, NINLARO, VELCADE |
| Stemline Menarini | $11.6B | Mar 1, 2026 | $600,000 | ORSERDU, ELZONRIS |
| Apellis Pharmaceuticals | $2.5B | Mar 1, 2026 | $300,000 | EMPAVELI |
| Galderma | $48B | Mar 1, 2026 | $300,000 | NEMLUVIO |

### High Confidence Pipeline

| Customer | Market Cap | Expected Sign | Notes |
|----------|-----------|---------------|-------|
| Teva Pharmaceuticals | $36.3B | Apr 1, 2026 | Enterprise Content Team |
| Sanofi Immunology | $113.8B | Mar 1, 2026 | Immunology Launch Products |
| Sanofi Oncology | $113.8B | Mar 1, 2026 | Oncology Products |
| Novartis | $304.9B | Mar 1, 2026 | Enterprise Content Team |
| Calliditas Therapeutics | $13.1B | Mar 1, 2026 | TARPEYO |
| NewAmsterdam Pharma | $3.6B | May 1, 2026 | Launch brand |

### Additional Pipeline (High Confidence)

- Johnson & Johnson Oncology ($526.8B)
- Acadia Pharmaceuticals ($4.4B)
- Eton Pharma ($406M)
- Sun Pharma ($43B)
- Azurity Pharmaceuticals ($1B)
- CSL Behring ($56.9B)
- Gilead Sciences ($155B)
- Chiesi ($3.4B)
- Recordati Rare Disease ($13.4B)
- Novocure ($1.5B)
- Alnylam Pharmaceuticals ($47.4B)
- Biogen ($24.1B)

### Medium Confidence Pipeline

- Bausch & Lomb ($2.6B)
- Geron Pharma ($836M)
- Axsome Therapeutics ($8.9B)
- Jazz Pharmaceuticals ($10.3B)
- Otsuka Pharmaceutical ($30.4B)
- Bayer Pharmaceuticals ($47.3B)
- Boehringer Ingelheim ($30B)
- EMD Serono ($66B)
- Vertex Pharmaceuticals ($112B)
- Idorsia ($1.2B)
- Sumitomo Pharma ($7.3B)
- 20+ additional conversations initiating

---

## 4. Team Wages

### Current Team (Jan 2026)

| Name | Role | Annual Salary |
|------|------|---------------|
| Aris Saxena | Co-Founder | $100,000 |
| Yiwen Li | Co-Founder | $100,000 |
| Ben Ramos | Founding AI Engineer | $180,000 |
| Arindam Sharma | Lead AI Engineer | $200,000 |
| Sai Bhandari | Founding Engineer | $200,000 |
| Alex Li | Founding Engineer | $160,000 |
| Rohan | Product Designer | $200,000 |
| Jesse Lee | VP of Ops | $180,000 |
| Andrew Shim | Lead Medical Copywriter | $200,000 |
| Dan Hanna | - | $96,000 |
| Vicky Zhou | Commercial Engagement | $175,000 |
| Adolfo, Chris, Michael | Contractors | $60,000 |
| Nayyer Ali | - | $40,000 |
| **Total Annual** | | **$1,891,000** |
| **Total Monthly** | | **$157,583** |

### Planned Hiring Budget

| Department | Roles | Total Budget |
|------------|-------|--------------|
| Sales | Head of Sales, 6 CELs, VP Marketing, 3 AEs | $2,200,000 |
| Product | 3 Full Stack, 2 AI Engineers, UI/UX, Frontend, VP Eng/PM | $1,830,000 |
| Other | Head of Talent | $200,000 |
| **Total** | | **$4,230,000** |

---

## 5. Gross Margin Analysis

### Unit Economics (Per Brand Team)

| Metric | Value |
|--------|-------|
| **Revenue** | |
| Average Revenue per Brand Team | $300,000 |
| | |
| **Variable Costs** | |
| Client Engagement Lead (1 per 3 brands) | $60,000 |
| Copywriter (1 per 6 brands) | $20,000 |
| Designer (1 per 6 brands) | $3,333 |
| Compute Costs | $6,000 |
| **Total Variable Cost per Brand** | $89,333 |
| | |
| **Profit** | |
| Variable Profit per Brand | $210,667 |
| **Gross Margin** | **70.2%** |

### Compute Cost Assumptions

| Parameter | Value |
|-----------|-------|
| Avg Tokens per Request | 50,000 |
| Avg Cost per Token | $0.0005 |
| Average Requests per Month | 20 |

---

## 6. Net Margin Analysis

### Break-Even Model (7 Brand Teams)

| Category | Amount |
|----------|--------|
| **Revenue** | |
| Brand Teams | 7 |
| Revenue per Brand | $300,000 |
| **Total Revenue** | **$2,100,000** |
| | |
| **Variable Costs** | |
| Variable Cost per Brand | $89,333 |
| **Total Variable Costs** | **$625,333** |
| | |
| **Fixed Costs** | |
| Engineering Salaries | $690,000 |
| Head of Ops Salary | $180,000 |
| Founder Salaries | $200,000 |
| Server Costs | $60,000 |
| Software Licenses | $30,000 |
| **Total Fixed Costs** | **$1,160,000** |
| | |
| **Profit** | |
| **Total Profit** | **$314,667** |
| **Net Margin** | **15.0%** |

---

## Key Model Assumptions

1. **ACV Growth**: 3% monthly increase in average deal size
2. **Expansion Rate**: Decreases from 3% to 1% monthly as customer base matures
3. **Sales Cycle**: Compresses from 4 months to 2 months over 21 months
4. **Conversion Rates**: Improve with brand recognition and case studies
5. **Marketing Spend**: 10% of revenue
6. **Professional Services**: 7% of revenue
7. **Contractors**: 1.5% of revenue
8. **Software/Hosting**: 2.4% of revenue
9. **Other Expenses**: 5% of revenue
